Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth E Palmer

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
BMJ Open|September 12, 2023
Development and validation of a product acceptability questionnaire for intranasal Q-Griffithsin COVID-19 prophylaxis (SPRAY PAL)Elizabeth Cash, Kailyn Deitz, Kevin L Potts, et al.
Structure (London, England : 1993)|July 18, 2006
Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate bindingNatasza E Ziółkowska, Barry R O'Keefe, Toshiyuki Mori, et al.
Journal of Virology|March 29, 2013
Griffithsin protects mice from genital herpes by preventing cell-to-cell spreadBriana Nixon, Martha Stefanidou, Pedro M M Mesquita, et al.
Vaccines|August 26, 2022
Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 VaccinationAlok R Amraotkar, Adrienne M Bushau-Sprinkle, Rachel J Keith, et al.
Frontiers in Bioengineering and Biotechnology|August 9, 2018
Technoeconomic Modeling of Plant-Based Griffithsin ManufacturingAatif Alam, Linda Jiang, Gregory A Kittleson, et al.
Proteins|March 7, 2007
Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsinNatasza E Ziółkowska, Shilpa R Shenoy, Barry R O'Keefe, et al.
Virology|September 17, 2011
A multimeric L2 vaccine for prevention of animal papillomavirus infectionsSubhashini Jagu, Nicole Malandro, Kihyuck Kwak, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 9, 2020
Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infectionsKevin M Tyo, Amanda B Lasnik, Longyun Zhang, et al.
Biosensors & Bioelectronics|October 19, 2020
Rapid detection of SARS-CoV-2 antibodies using electrochemical impedance-based detectorMohamed Z Rashed, Jonathan A Kopechek, Mariah C Priddy, et al.
Virology|February 10, 2006
Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applicationsMark L Smith, John A Lindbo, Stephan Dillard-Telm, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
BMJ Open|September 12, 2023
Development and validation of a product acceptability questionnaire for intranasal Q-Griffithsin COVID-19 prophylaxis (SPRAY PAL)Elizabeth Cash, Kailyn Deitz, Kevin L Potts, et al.
Structure (London, England : 1993)|July 18, 2006
Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate bindingNatasza E Ziółkowska, Barry R O'Keefe, Toshiyuki Mori, et al.
Journal of Virology|March 29, 2013
Griffithsin protects mice from genital herpes by preventing cell-to-cell spreadBriana Nixon, Martha Stefanidou, Pedro M M Mesquita, et al.
Vaccines|August 26, 2022
Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 VaccinationAlok R Amraotkar, Adrienne M Bushau-Sprinkle, Rachel J Keith, et al.
Frontiers in Bioengineering and Biotechnology|August 9, 2018
Technoeconomic Modeling of Plant-Based Griffithsin ManufacturingAatif Alam, Linda Jiang, Gregory A Kittleson, et al.
Proteins|March 7, 2007
Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsinNatasza E Ziółkowska, Shilpa R Shenoy, Barry R O'Keefe, et al.
Virology|September 17, 2011
A multimeric L2 vaccine for prevention of animal papillomavirus infectionsSubhashini Jagu, Nicole Malandro, Kihyuck Kwak, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 9, 2020
Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infectionsKevin M Tyo, Amanda B Lasnik, Longyun Zhang, et al.
Biosensors & Bioelectronics|October 19, 2020
Rapid detection of SARS-CoV-2 antibodies using electrochemical impedance-based detectorMohamed Z Rashed, Jonathan A Kopechek, Mariah C Priddy, et al.
Virology|February 10, 2006
Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applicationsMark L Smith, John A Lindbo, Stephan Dillard-Telm, et al.
Pageof 7